source
- FDA grants Capricor three-month extension to review DMD cell therapy dataThe U.S. Food and Drug Administration has given Capricor Therapeutics an additional three months to evaluate its Duchenne muscular dystrophy cell therapy after the agency asked for more information…
- Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorgAfter a “comprehensive evaluation,” Bristol Myers Squibb has pulled out of its partnership with Cellares and the cell therapy manufacturer will restructure as a result. Bristol Myers determined tha…Endpoints · 15m ago↗ source